Cite
Wells L, Vierra C, Hardman J, et al. Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2. Adv Ther (Weinh). 2021;2000210doi: 10.1002/adtp.202000210.
Wells, L., Vierra, C., Hardman, J., Han, Y., Dimas, D., Gwarada-Phillips, L. N., Blackeye, R., Eggers, D. K., LaBranche, C. C., Král, P., & McReynolds, K. D. (2021). Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2. Advanced therapeutics, 2000210. https://doi.org/10.1002/adtp.202000210
Wells, Lauren, et al. "Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2." Advanced therapeutics vol. (2021): 2000210. doi: https://doi.org/10.1002/adtp.202000210
Wells L, Vierra C, Hardman J, Han Y, Dimas D, Gwarada-Phillips LN, Blackeye R, Eggers DK, LaBranche CC, Král P, McReynolds KD. Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2. Adv Ther (Weinh). 2021 Feb 12;2000210. doi: 10.1002/adtp.202000210. Epub 2021 Feb 12. PMID: 33786368; PMCID: PMC7995185.
Copy
Download .nbib